Covid-19 has caused a dramatic loss of human life worldwide and has devastated countries' economies. Several COVID-19 vaccines under investigation are showing promising results. This Webinar will offer an overview of where we stand regarding vaccine development and will discuss the main challenges faced to ensure vaccines if successful, can help in the fight against [...]
If you believe the hype, a COVID-19 vaccine is just weeks away. Experts say widespread vaccination could help bring the deadly pandemic to its knees, so let's hope a safe, effective vaccine emerges from clinical trials. But don't count on getting your shots just yet. Click here to know more.
When President Donald Trump confirmed Oct. 2 that he was diagnosed with Covid-19, he received a cocktail of therapies — some of which hadn’t yet been approved for general use. Click here to read the full article
BioNTech, based in Mainz, Germany, announced positive results Monday about the Covid-19 vaccine it is developing with Pfizer. Click here to read more.
U.S pharmaceutical giant Pfizer and German biotech firm BioNTech said their coronavirus vaccine was more than 90% effective in preventing Covid-19 among those without evidence of prior infection, according to data published Monday from their late-stage vaccine trial. “It is a great day for science,” Pfizer CEO Albert Bourla told CNBC’s “Squawk Box” Monday morning. [...]
As of 8:00 a.m. ET Thursday, the unofficial U.S. tally stood at 9,488,875 cases and 233,734 deaths -- up by 103,369 (another new record) and 1,096, respectively, in the past 24 hours. Click here to read more.
New York University bioethics professor Dr. Arthur Caplan says human challenge studies whereby researchers inject volunteers with COVID-19 and then test the efficiency of vaccines, yields faster and more reliable data than large, traditional vaccine testing processes because they are controlling the environment. Click here to watch the video.
Arthur L. Caplan, PhD Director, Division of Medical Ethics, New York University Langone Medical Center, New York, NY discusses the known COVID-19 vaccine manufacturing and distribution considerations and the unknown timeline for public access. Click here to watch the video.
October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, the company inked an agreement to supply the European Union with its drug remdesivir as a treatment for COVID-19—a deal potentially worth more than $1 billion. Two weeks later, on 22 October, the U.S. [...]
